Population pharmacokinetics and CSF penetration of flucytosine in adults with HIV-associated cryptococcal meningoencephalitis. (1st March 2023)

• Record Type: Journal Article
• Authors: Stott, Katharine E; Ahmadu, Ajisa; Kajanga, Cheusisime; Moyo, Melanie; Gondwe, Ebbie; Chimang'anga, Wezzie; Chasweka, Madalitso; Unsworth, Jennifer; Jimenez-Valverde, Ana; Jagota, Bhavana; Shah, Reya V; Lawrence, David S; Lalloo, David G; Harrison, Tom; Jarvis, Joseph N; Hope, William; Mwandumba, Henry C
• Is Part Of: Journal of antimicrobial chemotherapy. Volume 78:Number 4(2023)
• Page Start: 1015
• Page End: 1022
• Publication Date: 2023-03-01
• Subjects: Anti-infective agents -- Periodicals; Chemotherapy -- Periodicals; 615.58
• DOI: 10.1093/jac/dkad038
• Languages: English
• ISSNs: 0305-7453

Abstract

Abstract: Background: There are limited data describing clinical flucytosine pharmacokinetics (PK). The variability of flucytosine partitioning into the CNS is not known. We described the interindividual variability in flucytosine PK in patients with HIV-associated cryptococcal meningoencephalitis. In addition, we quantified the extent and variability of CSF partitioning of flucytosine. Methods: A PK study was conducted in 64 patients with confirmed HIV-associated cryptococcal meningoencephalitis in Blantyre, Malawi. A four-compartment PK model was developed, and Monte Carlo simulations were performed with flucytosine administered at different doses and in different schedules. Results: The estimated mean apparent volume of the central compartment was 17.50 (SD 9.99) L; mean apparent clearance was 5.88 (SD 3.35) L/h; mean apparent volume of the CNS compartment was 41.73 (SD 13.66) L. From the Bayesian posterior estimates, AUC24 values at steady state (144–168 h) with doses of 25 mg/kg q6h were median (IQR) 890.38 (603.81–1213.70) mg.h/L in plasma and 595.66 (425.69–776.64) mg.h/L in CSF. The ratio of CSF:plasma AUC24 was 0.69 (IQR 0.58–0.82). Conclusions: This study revealed significant interindividual variability in flucytosine PK in plasma and CSF in patients with HIV-associated cryptococcal meningoencephalitis. The population PK model is a first critical step for revised flucytosine regimens that maximize fungal killing and minimize toxicity and the emergence of resistance.